Navigation Links
Solving the 50-year-old puzzle of thalidomide
Date:11/17/2009

Research into the controversial drug thalidomide reveals that the mechanism through which the drug causes limb defects is the same process which causes it to damage internal organs and other tissues. The article, published in Bio-Essays, outlines the challenges surrounding thalidomide research and claims that confirmation of a 'common mechanism' could lead to new treatments for Leprosy, Crohn's Disease, AIDS and some forms of cancer.

Thalidomide was used in over 46 countries following its launch in 1957, but its side effects led to over 10000 children being born with birth defects and the drug was subsequently banned in 1962. However, the drug is now experiencing a renaissance worldwide, particularly across Africa and South America where new cases of thalidomide-induced limb defects are now occurring. This, argues Dr Neil Vargesson of the University of Aberdeen, raises the urgency for research which can target and isolate the drug's negative side effects.

"The mere mention of thalidomide instils fear in some people to this day as it caused the biggest medical disaster in history," said Vargesson. "However it still raises hopes for the treatments of diseases such as Leprosy and multiple myeloma."

Dr Vargesson and his team were the first to demonstrate how the drug causes limb defects by targeting immature blood vessels and now this latest article attempts to link all previous models of thalidomide action together to create one central model. This model proposes that all thalidomide associated defects could be caused by the same 'common mechanism', primarily an effect on angiogenesis, the growth of new blood vessels.

The understanding that the drug's targeting of blood vessels is a 'common mechanism' and the root cause of thalidomide's other side effects raises the possibility of producing a safer form of the drug which can isolate this mechanism and retain clinical benefits.

"Understanding this mechanism resolves a 50-year-old puzzle," concluded Vargesson, "it answers the questions asked by scientists since the first cases were identified in 1958. The possibility of producing analogues of the drug for targeting specific conditions without the devastating side effects is now a very real possibility."


'/>"/>

Contact: Ben Norman
Benorman@wiley.com
44-124-377-0375
Wiley-Blackwell
Source:Eurekalert

Related medicine news :

1. Celiac Disease Provides Clues To Solving Autoimmunity
2. Study finds autistics better at problem-solving
3. MonoSol Rx Announces FDA Acceptance of NDA for Ondansetron Orally Dissolving Film Strip
4. Body movements can influence problem solving, researchers report
5. MonoSol Rx and Strativa Pharmaceuticals Submit New Drug Application for Ondansetron Orally Dissolving Film Strip
6. Study shows potential for resolving type 2 diabetes with bariatric surgery
7. Eating Disorder International Symposium - Shoreline Center for Eating Disorder Treatment and Eating Disorder Awareness Week, Converge on Solving the Life-Threatening Illness
8. Resolving to Break an Addictive Habit?
9. New Strategies for the New Year: Resolving to break an addiction? Help from Harvard Medical School
10. Prevention is the Key to Solving Health Care Crisis;
11. Study further defines potential role of fish-based fatty acids in resolving, preventing asthma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... ... 24, 2017 , ... Judy Buchanan, co-owner of Serenity Natural ... Judy says, “I am passionate about sharing Reiki as a holistic, complementary therapy ... challenging time.” , A Certified Medical Reiki™ Master trained by Raven Keys Medical ...
(Date:3/24/2017)... ... ... “The Adventures of Joey, The Dog Who Barks at Puddles”: a boisterous story about ... as God intended. “The Adventures of Joey, The Dog Who Barks at Puddles” is ... for writing, especially about truth and human behavior. , Published by Christian Faith Publishing, ...
(Date:3/23/2017)... ... March 23, 2017 , ... Texas Physical Therapy Specialists (TexPTS) ... Gruene Road in Building 2. The clinic is the group’s second in New Braunfels ... opening the company’s second New Braunfels location brings things full circle for the group, ...
(Date:3/23/2017)... ... March 23, 2017 , ... Dilger-Maxwell ... of the Norwalk and Vermillion areas, celebrates the newest charity campaign in ... nonprofit, community-based substance abuse prevention and peer recovery support organization providing vital ...
(Date:3/23/2017)... ... March 23, 2017 , ... ... owned and organized by HMP Communications Holdings, LLC, today announced that RestorixHealth® ... its nationwide network of wound centers interested in becoming Certified Wound Specialist Physicians ...
Breaking Medicine News(10 mins):
(Date:3/23/2017)... DIEGO and VANCOUVER, British Columbia ... (NASDAQ: SPHS ) (the "Company" or "Sophiris"), ... the treatment of urological diseases, today announced that data ... evaluated the drug as a focal treatment for localized ... March 26, 2017 at the 32 nd Annual ...
(Date:3/23/2017)... 23, 2017 Research and Markets has announced ... report to their offering. ... The global oxygen therapy devices market to grow ... The report, Global Oxygen Therapy Devices Market 2017-2021, has been ... experts. The report covers the market landscape and its growth prospects ...
(Date:3/23/2017)... Research and Markets has announced the addition ... their offering. ... The global capillary electrophoresis market to grow at a CAGR of ... Capillary Electrophoresis Market 2017-2021, has been prepared based on an in-depth ... market landscape and its growth prospects over the coming years. The ...
Breaking Medicine Technology: